Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2-agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers-Reference-Cited by-同舟云学术

Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2-agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers

Published:2014-02-20 Issue:4 Volume:3 Page:305-313
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:

Author:

Norris Virginia¹,Ambery Claire¹,Riley Trevor¹

Affiliation:

1. GlaxoSmithKline; UK

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Reference24 articles.

1. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html

2. Effect of the combination of two bronchodilators on breathlessness in patients with chronic obstructive pulmonary disease. A crossover clinical trial;Sansores;Arch Med Res.,2003

3. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper;Celli;Eur Respir J.,2004

4. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD;Cazzola;Pulm Pharmacol Ther.,2010

5. THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoreceptor agonist (MABA) that binds in a bimodal and multivalent manner;Steinfeld;Mol Pharmacol.,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease

;Journal of Experimental Pharmacology;2020-12

2. Pharmacokinetics, Excretion, and Mass Balance of [14 C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men;Clinical Pharmacology in Drug Development;2018-09-19

3. Triple inhaled therapy for chronic obstructive pulmonary disease;Drug Discovery Today;2016-11

4. Open-Label, Randomized, 6-Way Crossover, Single-Dose Study to Determine the Pharmacokinetics of Batefenterol (GSK961081) and Fluticasone Furoate When Administered Alone or in Combination;Clinical Pharmacology in Drug Development;2016-06-26

5. Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial;Drugs in R&D;2015-08-19